GTBIFGreen Thumb Industries
GTBIF
Green Thumb Industries6,228
Mkt Cap
$1.66BVolume
222,791.0052W High
$10.4352W Low
$4.80PE Ratio
14.62GTBIF Fundamentals
Price
$7.58Prev Close
$7.50Open
$7.3750D MA
$7.12Beta
0.77Avg. Volume
607,909.05EPS (Annual)
$0.4819P/B
0.90Rev/Employee
$235,059.00$2,142.61
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
Green Thumb Industries Inc. (GTBIF) Moves 10.0% Higher: Will This Strength Last?
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Curaleaf Launches Buyback Program: Time to Get Bullish on the Stock?
CURLF's $83M buyback lifts shares, but U.S. pricing pressure and rising losses cloud the outlook despite strong international growth momentum.
Boston Scientific (BSX) Q1 Earnings Match Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of +0.59% and +0.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?
Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?
Cannabis Stock VRNO Rises 40% in a Year: Time to Buy, Sell or Hold?
Verano stock has surged more than 40% in a year amid U.S. marijuana rescheduling optimism, but revenue headwinds and rising competition may keep investors cautious.
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.
Trump Orders Federal Action to Accelerate Cannabis Research Access
President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...
Trump Orders Federal Action to Accelerate Cannabis Research Access
President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...
<
1
2
...
>
Compact View
Not available
Not available